sulfinpyrazone sulfinpyrazone sulfinpyrazone is a uricosuric medication used to treat gout. it also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of adp and thromboxane. sulfinpyrazoneclinical datatrade namesanturan, anturane, apo-sulfinpyrazoneahfs/drugs.commonographmedlineplusa682339routes ofadministrationby mouth intravenousatc codem04ab02 (who) pharmacokinetic dataprotein binding98–99%metabolismliverexcretionkidneyidentifiers iupac name 1,2-diphenyl-4-pyrazolidine-3,5-dione cas number57-96-5 ypubchem cid5342iuphar/bps5826drugbankdb01138 ychemspider5149 yuniiv6ofu47k3wkeggd00449 ychebichebi:9342 ychemblchembl832 ycomptox dashboard (epa)dtxsid0023618 echa infocard100.000.325 chemical and physical dataformulac23h20n2o3smolar mass404.48 g·mol−13d model (jsmol)interactive image smiles o=c2n(c1ccccc1)n(c(=o)c2ccs(=o)c3ccccc3)c4ccccc4 inchi inchi=1s/c23h20n2o3s/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21h,16-17h2 ykey:mbggbvcuivrrbf-uhfffaoysa-n y (verify) like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney. contraindications sulfinpyrazone must not be used in persons with renal impairment or a history of uric acid kidney stones. research trial have found that, sulfinpyrazone taken in specific daily dose immediately following a patient having suffered from a myocardial infarction seem to drastically reduce the incidence of sudden death by as much as 43% and cardiac mortality by 32% in the 24 months following their heart attack.